Last reviewed · How we verify

NCT06211088

Famotidine Versus Placebo in Emergency Pediatric Surgery As a Risk to Postoperative Nausea and Vomiting

Completed NA Last updated 11 March 2025
What this trial tests

NA trial testing famotidine plus10ml normal saline in Postoperative Nausea and Vomiting in 50 participants. Completed in 30 January 2025.

Timeline
1 August 2024
Primary endpoint
30 December 2024
30 January 2025

Quick facts

Lead sponsorAswan University Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeother
Enrollment50
Start date1 August 2024
Primary completion30 December 2024
Estimated completion30 January 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Aswan University Hospital

Who can join

Adults 2 to 13, any sex, with Postoperative Nausea and Vomiting. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by using 5mg famotidine versus placebo as a risk factor of PONV.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Postoperative Nausea and Vomiting

Currently open trials in the same condition.

Other Aswan University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06211088.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing